

10727997

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	FEB 26	MEDLINE reloaded with enhancements
NEWS	31	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),

10727997

AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:14:35 ON 06 MAR 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:14:42 ON 06 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2007 HIGHEST RN 924962-30-1

DICTIONARY FILE UPDATES: 5 MAR 2007 HIGHEST RN 924962-30-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10727997AF.str

10727997



chain nodes :

1 2 3 4 5 7 8 9

ring/chain nodes :

6

chain bonds :

1-2 1-8 2-3 2-4 3-5 5-6 5-7 8-9

exact/norm bonds :

1-2 1-8 2-3 2-4 3-5 5-6 5-7 8-9

G1:O,S

Match level :

1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom

Generic attributes :

1:

Saturation : Unsaturated

Type of Ring System : Monocyclic

Element Count :

Node 1: Limited

C,C4-6

O,O0

S,S0-1

N,N0

10727997

Node 9: Limited

O,00-1

S,S0


N,N0

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:15:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1757 TO ITERATE

100.0% PROCESSED 1757 ITERATIONS

16 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 32626 TO 37654

PROJECTED ANSWERS: 80 TO 560

L2 16 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:15:07 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 35478 TO ITERATE

100.0% PROCESSED 35478 ITERATIONS

270 ANSWERS

SEARCH TIME: 00.00.01

L3 270 SEA SSS FUL L1

=> fil hcplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'HCPLUS' ENTERED AT 14:15:15 ON 06 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10727997

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 5 Mar 2007 (20070305/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 14 L3

=> d ed ibib abs hitstr 1-14

10727997

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 15 Dec 2006
 ACCESSION NUMBER: 2006:1312018 HCAPLUS
 DOCUMENT NUMBER: 146:55527
 TITLE: Melanocortin 4 receptor modulators as pharmacological chaperones for treating obesity and methods for screening for such modulators
 INVENTOR(S): Fan, Jian-Qiang; Vanlencano, Ken; Lee, Gary; Bouvier, Michel
 PATENT ASSIGNER(S): Amicus Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006133098	A2	20061214	WO 2006-US21752	20060605
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KH, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 2007021433 A1 20070125 US 2006-446429 20060602 PRIORITY APPL. INFO.: US 2005-687648P P 20050603 US 2006-799688P P 20060512 US 2006-446429 A 20060602				


AB The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacol. chaperone for the MC4R. The invention provides MC4R pharmacol. chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacol. chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface. Thus, recombinant HEX-293T or COS-7 cells expressing genes for human SS9C, R165W, or R165Q MC4R mutants exhibited reduced levels of surface MC4R relative to these same cells expressing the wild-type MC4R gene. Administration of two MC4R antagonists increased the surface expression of these mutants.

IT 916250-19-6
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (melanocortin 4 receptor modulators as pharmacol. chaperones for treating obesity and methods for screening for such modulators)

L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 16 Mar 2006
 ACCESSION NUMBER: 2006:232893 HCAPLUS
 DOCUMENT NUMBER: 144:403787
 TITLE: Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonists
 AUTHOR(S): Vos, Tricia J.; Balani, Suresh; Blackburn, Christopher; Chau, Ryan W.; Danca, M. Diana; Drabic, Stacey V.; Farrer, Cheryl A.; Patane, Michael A.; Stoud, Stephen G.; Yowe, David L.; Claiborne, Christopher F.
 CORPORATE SOURCE: Millennium Pharmaceuticals, Inc., Cambridge, MA, 02139, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(8), 2302-2305
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:403787

AB The identification and optimization of a series of acylguanidine-based melanocortin-4 receptor antagonists is discussed.
 IT 705978-50-3P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (acylguanidine-based melanocortin-4 receptor antagonists)


RN 705978-50-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




IT 705977-45-3P 705977-46-4P 705977-48-6P
 705977-49-7P 705977-57-7P 705977-58-8P
 705977-59-9P 705977-70-4P 705977-81-7P
 705977-87-3P 705977-90-8P 705977-93-1P
 705978-14-9P 705978-24-1P 705978-36-5P
 705978-96-7P 705979-00-6P 705979-01-7P
 705979-02-8P 705979-11-9P 705979-13-1P
 884538-31-2P 884538-32-3P 884538-34-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (acylguanidine-based melanocortin-4 receptor antagonists)

RN 705977-45-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[(butylamino)iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 916250-19-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[[(1-ethyl-4-piperidinyl)methyl]amino]iminomethyl]- (CA INDEX NAME)




L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705977-46-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(2-methylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 705977-48-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(2-(1-pyrrolidinyl)ethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-49-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[(2-cyclohexylethyl)amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)

For 1
 ND


App. work

10727997


L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705977-57-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-58-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[3-(4-methyl-1-piperazinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-59-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[3-(1-piperidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705977-90-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]methylene]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-93-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]methylene]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-14-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(cyclohexylamino)propyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705977-70-4 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705977-81-7 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705977-87-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]methylene]-3-fluoro- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-24-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)



RN 705978-36-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(methyl[1-naphthalenylmethyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A


PAGE 2-A




RN 705978-96-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-(1-piperidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705979-00-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(3,4-dihydro-2(1H)-isoquinolinyl)butyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705979-01-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-(octahydro-2(1H)-isoquinolinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705979-02-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-[methyl(phenylmethyl)amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705979-11-9 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705979-13-1 HCAPLUS
 CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-2-[2-(3,5-dimethoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 884538-31-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(1-ethyl-4-piperidinyl)methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 884538-32-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-chlorophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 884538-34-5 HCAPLUS
 CN Benzamide, 2-[2-(2-chlorophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



IT 884538-28-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (acylguanidine-based melanocortin-4 receptor antagonists)

RN 884538-28-7 HCAPLUS
 CN Benzamide, N-(aminoinomethyl)-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 18 Jun 2004

ACCESSION NUMBER: 2004:493667 HCAPLUS

DOCUMENT NUMBER: 141:54200

TITLE: Preparation of aroylguanidines as melanocortin MC4 receptor antagonists.

INVENTOR(S): Vos, Tricia J.; Patane, Michael; Solomon, Michael E.; Blackburn, Christopher; Danca, Mihaela D.

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050610	A2	20040617	WO 2003-US38369	20031204
WO 2004050610	A3	20040826		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TH, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508914	A1	20040617	CA 2003-2508914	20031204
AU 2003297629	A1	20040623	AU 2003-297629	20031204
US 2004147746	A1	20040729	US 2003-727997	20031204
EP 1590338	A2	20051102	EP 2003-812495	20031204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006509014	T	20060316	JP 2004-557520	20031204
PRIORITY APPLN. INFO.: US 2002-430789P P 20021204 WO 2002-US38369 W 20031204				

OTHER SOURCE(S): MARPAT 141:54200

G1

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



Title compds. [1: X = O, S; G = C:(NR3)NR2L2NR4R5, C:(NR3)NR2L3R14, etc.; L2 = (substituted) (interrupted) alkylidene which may form part of a 3-7 membered ring; L3 = bond, L2: R1 = H, aliphatic; R2 = H, aliphatic, aryl, aralkyl, electron pair; R3 = H, aliphatic, aryl, aralkyl; R4 = H, aliphatic, aliphaticylcarbonyl, aryl, heteroaryl, aralkyl, heteroalkyl, etc.; R5 = H, aliphatic; R4R5N = (substituted) mono-, bi- or tricyclic ring; A = atoms to form a (substituted) 5-membered heteroaryl, 6-membered aryl ring; R14 = H, aliphatic, aryl, heteroaryl, aralkyl, heteroalkyl, heterocyclyl; NR3R14 = (substituted) mono-, bi-, or tricyclic (aromatic) heterocyclyl; Q = (substituted) (interrupted) alkylidene; Ph ring attached to Q may be substituted], were prepared as melanocortin MC4 receptor antagonists (no data). Thus, 1-[2-[(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]-2-methylisothiourea, Et3N, and 1-(3-aminopropyl)-2-pipecoline were refluxed in xylene to give N-[2-[(2-(5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]-N'-[3-(2-methylpiperidin-1-yl)propyl]guanidine as the bisformate salt.

705977-44-2P 705977-45-3P 705977-46-4P
705977-47-5P 705977-48-6P 705977-49-7P
705977-50-0P 705977-51-1P 705977-52-2P
705977-53-3P 705977-54-4P 705977-55-5P
705977-56-6P 705977-57-7P 705977-58-8P
705977-59-9P 705977-60-2P 705977-61-3P
705977-62-4P 705977-63-5P 705977-64-6P
705977-65-7P 705977-66-8P 705977-67-9P
705977-68-0P 705977-69-1P 705977-70-4P
705977-71-5P 705977-72-6P 705977-73-7P
705977-74-8P 705977-75-9P 705977-76-0P
705977-77-1P 705977-78-2P 705977-79-3P
705977-80-3P 705977-81-4P 705977-82-5P
705977-83-6P 705977-84-0P 705977-85-1P
705977-86-2P 705977-87-3P 705977-88-4P
705977-89-5P 705977-90-6P 705977-91-7P
705977-92-8P 705977-93-1P 705977-94-2P
705977-95-3P 705977-96-4P 705977-97-5P
705977-98-6P 705978-02-5P 705978-03-6P
705978-04-7P 705978-05-8P 705978-06-9P
705978-07-0P 705978-08-1P 705978-09-2P
705978-10-3P 705978-11-4P 705978-12-5P
705978-13-6P 705978-14-7P 705978-15-8P
705978-16-9P 705978-17-0P 705978-18-1P
705978-19-2P 705978-20-3P 705978-21-4P
705978-22-5P 705978-23-6P 705978-24-7P
705978-25-8P 705978-26-9P 705978-27-0P

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

705978-29-6P 705978-30-7P 705978-31-0P
705978-32-1P 705978-33-2P 705978-34-3P
705978-35-4P 705978-36-5P 705978-37-6P
705978-38-7P 705978-39-8P 705978-40-1P
705978-41-2P 705978-42-3P 705978-43-4P
705978-44-5P 705978-45-6P 705978-46-7P
705978-47-8P 705978-48-9P 705978-49-0P
705978-50-3P 705978-51-4P 705978-52-5P
705978-53-6P 705978-54-7P 705978-55-8P
705978-56-9P 705978-57-0P 705978-58-1P
705978-59-2P 705978-60-3P 705978-61-4P
705978-62-5P 705978-63-6P 705978-64-7P
705978-65-8P 705978-66-9P 705978-67-0P
705978-68-3P 705978-69-4P 705978-70-5P
705978-71-6P 705978-72-7P 705978-73-8P
705978-74-1P 705978-75-2P 705978-76-3P
705978-77-4P 705978-78-5P 705978-79-6P
705978-80-7P 705978-81-8P 705978-82-9P
705978-83-0P 705978-84-1P 705978-85-2P
705978-86-3P 705978-87-4P 705978-88-5P
705978-89-6P 705978-90-7P 705978-91-8P
705978-92-9P 705978-93-0P 705978-94-1P
705978-95-2P 705978-96-3P 705978-97-4P
705978-98-5P 705978-99-6P 705979-00-7P
705979-01-8P 705979-02-9P 705979-03-0P
705979-04-1P 705979-05-2P 705979-06-3P
705979-07-4P 705979-08-5P 705979-09-6P
705979-10-7P 705979-11-8P 705979-12-9P
705979-13-0P 705979-14-1P 705979-15-2P
705979-16-3P 705979-17-4P 705979-18-5P
705979-19-6P 705979-20-7P 705979-21-8P
705979-22-9P 705979-23-0P 705979-24-1P
705979-25-2P 705979-26-3P 705979-27-4P
705979-28-5P 705979-29-6P 705979-30-7P
705979-31-8P 705979-32-9P 705979-33-0P
705979-34-1P 705979-35-2P 705979-36-3P
705979-37-4P 705979-38-5P 705979-39-6P
705979-40-7P 705979-41-8P 705979-42-9P
705979-43-0P 705979-44-1P 705979-45-2P
705979-46-3P 705979-47-4P 705979-48-5P
705979-49-6P 705979-50-7P 705979-51-8P
705979-52-9P 705979-53-0P 705979-54-1P
705979-55-2P 705979-56-3P 705979-57-4P
705979-58-5P 705979-59-6P 705979-60-7P
705979-61-8P 705979-62-9P 705979-63-0P
705979-64-1P 705979-65-2P 705979-66-3P
705979-67-4P 705979-68-5P 705979-69-6P
705979-70-7P 705979-71-8P 705979-72-9P
705979-73-0P 705979-74-1P 705979-75-2P
705979-76-3P 705979-77-4P 705979-78-5P
705979-79-6P 705979-80-7P 705979-81-8P
705979-82-9P 705979-83-0P 705979-84-1P
705979-85-2P 705979-86-3P 705979-87-4P
705979-88-5P 705979-89-6P 705979-90-7P
705979-91-8P 705979-92-9P 705979-93-0P
705979-94-1P 705979-95-2P 705979-96-3P
705979-97-4P 705979-98-5P 705979-99-6P


RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aroylguanidines as melanocortin MC4 receptor antagonists)


RN 705977-44-2 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




705977-45-3 HCAPLUS
Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[(butylamino)imino]methyl]-3-fluoro- (9CI) (CA INDEX NAME)



705977-46-4 HCAPLUS
Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[2-methylpropyl]amino]methyl]- (9CI) (CA INDEX NAME)



705977-47-5 HCAPLUS
Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[(cyclopentylamino)imino]methyl]-3-fluoro- (9CI) (CA INDEX NAME)



546/246 - COTD21/14
574/331 PkK31/445


564/183
COTC 2331

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705977-48-6 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(2-(1-pyrrolidinyl)ethyl)amino)methyl]]- (9CI) (CA INDEX NAME)

54/369
54/428


RN 705977-49-7 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[2-(cyclohexylethyl)amino]iminoethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-50-0 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(1-phenylethyl)amino)methyl]]- (9CI) (CA INDEX NAME)



RN 705977-54-4 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[(3-chlorophenyl)methyl][2-(1-pyrrolidinyl)ethyl]amino]iminoethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705977-55-5 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(3-(4-morpholinyl)propyl)amino)methyl]]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705977-51-1 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(2-thienylmethyl)amino)methyl]]- (9CI) (CA INDEX NAME)

349/74
54/438

RN 705977-52-2 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(3-pyridinylmethyl)amino)methyl]]- (9CI) (CA INDEX NAME)



RN 705977-53-3 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(1-phenyl-2-(1-pyrrolidinyl)ethyl)amino)methyl]]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705977-54-4 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[(3-chlorophenyl)methyl][2-(1-pyrrolidinyl)ethyl]amino]iminoethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705977-55-5 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(3-(4-morpholinyl)propyl)amino)methyl]]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

544/168
54/237.8


RN 705977-56-6 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(1H-imidazol-1-yl)propyl]amino]iminoethyl]]- (9CI) (CA INDEX NAME)

548/336.5
54/379

RN 705977-57-7 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminoethyl]]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-58-8 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(3-(4-methyl-1-piperazinyl)propyl)amino)methyl]]- (9CI) (CA INDEX NAME)

10727997


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705977-59-9 HCAPLUS
CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[3-(1-piperidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-60-2 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[butylamino]imino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-61-3 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino(2-methylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705977-64-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino(2-(1-pyrrolidinyl)ethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-65-7 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino(2-(diethylamino)ethyl)methylamino]imino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705977-62-4 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[cyclopentylamino]imino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-63-5 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino(3-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705977-66-8 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 705977-67-9 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino(4-diethylamino)ethyl)amino]imino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-68-0 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino(4-morpholinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-69-1 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-ethyl-2-pyrrolidinyl)methyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705977-70-4 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705977-74-8 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-79-3 HCAPLUS
CN Benzamide, 3-fluoro-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-2-[2-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705977-71-5 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(dibutylamino)propyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705977-72-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705977-73-7 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(1-piperidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705977-80-6 HCAPLUS
CN Benzamide, 3-fluoro-N-[[[3-(4-morpholinyl)propyl]amino]methyl]-2-[2-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705977-81-7 HCAPLUS
CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705977-82-8 HCAPLUS
CN Benzamide, 2-[2-(2-bromo-5-chlorophenyl)ethyl]-3-fluoro-N-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)

10727997


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705977-83-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-5-chlorophenyl)ethyl]-N-[[4-(diethylamino)-1-methylbutyl]amino]methylene]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-84-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[(methylamino)[3-(1-pyrrolidinyl)propyl]amino]methylene]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705977-88-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[(methylamino)[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]methylene]- (9CI) (CA INDEX NAME)




RN 705977-89-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[(1-methylethyl)amino][3-(2-methyl-1-piperidinyl)propyl]amino]methylene]- (9CI) (CA INDEX NAME)




RN 705977-90-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[4-(diethylamino)-1-methylbutyl]amino][1-methylethyl]amino]methylene]-3-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 705977-85-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(1H-imidazol-1-yl)propyl]amino]methylene]- (9CI) (CA INDEX NAME)




RN 705977-86-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[(methylamino)[3-(2-methyl-1-piperidinyl)propyl]amino]methylene]- (9CI) (CA INDEX NAME)




RN 705977-87-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[4-(diethylamino)-1-methylbutyl]amino]methylene]-3-fluoro- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705977-91-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[3-(1H-imidazol-1-yl)propyl]amino][1-methylethyl]amino]methylene]- (9CI) (CA INDEX NAME)




RN 705977-92-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]methylene]- (9CI) (CA INDEX NAME)




10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 705977-93-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino] (phenylamino)methylene]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705977-94-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(2-methyl-1-piperidiny)propyl]amino] (phenylamino)methylene]- (9CI) (CA INDEX NAME)




RN 705977-95-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(1H-imidazol-1-yl)propyl]amino] (phenylamino)methylene]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705977-98-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-3-oxobutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705978-02-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino] (methylamino)methylene]- (9CI) (CA INDEX NAME)




RN 705978-03-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino) cyclohexyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-07-0 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[2-(diethylamino)ethyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705977-96-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)cyclohexyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705977-97-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)cyclopentyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-08-1 HCAPLUS
 CN 3-Thiophenecarboxamide, 4-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(dimethylamino)propyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)



RN 705978-11-6 HCAPLUS
 CN Proline, 1-[3-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]propyl]- (9CI) (CA INDEX NAME)




10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705978-12-7 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(dimethylamino)-2,2-dimethylpropyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-13-8 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-oxo-3-(1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-17-2 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(dimethylamino)cyclohexyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705978-18-3 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-oxo-3-(1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




RN 705978-14-9 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(cyclohexylamino)propyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705978-15-0 HCAPLUS

CN Benzamide, N-[(1-azabicyclo[2.2.2]oct-3-ylamino)iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-16-1 HCAPLUS

CN 1-Pyrrolidinedipentanoic acid, α-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



RN 705978-17-2 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(dimethylamino)cyclohexyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)

PAGE 2-A



RN 705978-20-7 HCAPLUS

CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)-2,2-difluoropropyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-21-8 HCAPLUS


CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)-2-hydroxypropyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)

10727997


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-22-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]ethyl-N-[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-23-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methyl-7-benzofuranyl)ethyl]ethyl-N-[[4-(diethylamino)-1,1-dimethylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-24-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]ethyl-3-chloro-N-[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705978-27-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]ethyl-3-fluoro-N-[[5-(1-piperidinyl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-28-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]ethyl-3-fluoro-N-[[5-(1-pyrrolidinyl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-25-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]ethyl-3-chloro-N-[[4-(1-pyrrolidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-26-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]ethyl-3-chloro-N-[[4-(1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705978-29-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]ethyl-3-fluoro-N-[[4-[(1R)-1-phenylethyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705978-30-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]ethyl-3-fluoro-N-[[4-[(1R)-1-phenylethyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705978-31-0 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]ethyl-3-chloro-N-[[4-(1-morpholinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-32-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]ethyl-3-fluoro-N-[[4-(1-morpholinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)

10727997


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-33-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-[[4-(methylsulfonyl)phenyl)methyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705978-34-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-[[1-methylethyl] (phenylmethyl)amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-35-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[4-[[2-

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-A



RN 705978-37-6 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[imino[[4-(1-pyrrolidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-38-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-ethoxy-N-[imino[[4-(1-pyrrolidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-39-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[imino[[6-methyl-6-azabicyclo[3.1.1]hept-3-yl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (dimethylamino)ethyl] (phenylmethyl)amino]butyl]amino]methyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-36-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-[methyl(1-naphthalenyl)methyl]amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-40-1 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[imino[[4-(piperidinyl)methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-41-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-chloro-N-[imino[[4-(piperidinyl)methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-42-3 HCAPLUS
 CN Benzamide, 2-[2-(5-cyano-7-benzofuranyl)ethyl]-3-fluoro-N-[imino[[4-(piperidinyl)methyl]amino]methyl]- (9CI) (CA INDEX NAME)

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705978-43-4 HCAPLUS
 CN Benamide, 2-[(2-(5-bromo-2-methoxyphenyl)ethyl)-3-chloro-N-[[[1-(cyclopropylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705978-44-5 HCAPLUS
 CN Benamide, N-[[[trans-4-aminocyclohexyl]amino]iminomethyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705978-48-9 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino[(4-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 705978-49-0 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino[(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-50-3 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(4-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-51-4 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-N-[[[1-(cyclopropylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705978-45-6 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[imino[(3-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-46-7 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(4-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)





RN 705978-47-8 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[imino[(1H-indol-3-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-52-5 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-(cyclopropylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705978-53-6 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(3-piperidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-54-7 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[(3-pyrrolidinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705978-55-8 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-56-9 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-(cyclopropylmethyl)-3-piperidinyl]methyl]amino]methyl]-3-fluoro- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-57-0 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(phenylmethyl)-3-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-58-1 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(phenylmethyl)-4-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-59-2 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(trans-4-hydroxycyclohexyl)amino]methyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705978-60-5 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(trans-4-aminocyclohexyl)amino]methyl]methyl]- (9CI) (CA INDEX NAME)




RN 705978-61-6 HCAPLUS
 CN Benamide, N-[[[1-(trans-4-aminocyclohexyl)amino]methyl]methyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 705978-62-7 HCAPLUS
 CN Benamide, N-[[[1-(trans-4-aminocyclohexyl)amino]methyl]methyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705978-63-8 HCAPLUS
 CN Benamide, N-[[[1-(trans-4-aminocyclohexyl)amino]methyl]methyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 705978-64-9 HCAPLUS
 CN Benamide, N-[[[1-(trans-4-aminocyclohexyl)amino]methyl]methyl]-2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.











RN 705978-65-0 HCAPLUS
 CN Benamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-(cyclopentylmethyl)-4-piperidinyl]methyl]amino]methyl]-3-fluoro-


10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(9CI) (CA INDEX NAME)RN 705978-66-1 HCAPLUS
CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(1H-imidazol-4-ylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)RN 705978-67-2 HCAPLUS
CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(1-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)RN 705978-68-3 HCAPLUS
CN 4-Piperidinepropanoic acid, beta-[[[2-[2-(5-bromo-2-

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705978-71-8 HCAPLUS
CN 4-Piperidinepropanoic acid, beta-[[[2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)RN 705978-72-9 HCAPLUS
CN 4-Piperidineacetic acid, alpha-[[[2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)RN 705978-73-0 HCAPLUS
CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]methyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)RN 705978-74-1 HCAPLUS
CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[[1-(1-L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]-1-[(1,1-dimethylethoxycarbonyl)- (9CI) (CA INDEX NAME)RN 705978-69-4 HCAPLUS
CN 4-Piperidineacetic acid, alpha-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)RN 705978-70-7 HCAPLUS
CN 4-Piperidinepropanoic acid, beta-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]- (9CI) (CA INDEX NAME)L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methyl-2-pyrrolidinyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)RN 705978-76-3 HCAPLUS
CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chloro-N-[[[1-(4-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)RN 705978-77-4 HCAPLUS
CN Cyclopropanecarboxylic acid, 2-[[4-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]methyl]-1-piperidinyl]methyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


RN 705978-78-5 HCAPLUS
CN Benzanide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[1-(4-methylpropylamino)butyl]amino]methyl]- (9CI) (CA INDEX NAME)

10727997


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-79-6 HCAPLUS
CN Benzamide, 2-[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]aminoiminomethyl]amino]butyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 705978-80-9 HCAPLUS
CN Benzamide, 2-[2-((5-bromo-7-benzofuranyl)ethyl)-3-chlorobenzoyl]aminoiminomethyl]amino]butyl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 705978-81-0 HCAPLUS
CN Benzamide, 2-[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]aminoiminomethyl]amino]butyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705978-85-4 HCAPLUS
CN 3-Piperidinecarboxamide, 1-[4-[[[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 705978-86-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[[[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-82-1 HCAPLUS
CN 3-Piperidinecarboxamide, 1-[4-[[[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 705978-83-2 HCAPLUS
CN 3-Piperidinecarboxamide, 1-[4-[[[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 705978-84-3 HCAPLUS
CN 3-Piperidinecarboxamide, 1-[4-[[[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 705978-87-6 HCAPLUS
CN Benzamide, 2-[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]aminoiminomethyl]amino]butyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 705978-88-7 HCAPLUS
CN 2H-Pyrrolidinium, 2-(aminocarbonyl)-1-[4-[[[2-((5-bromo-2-methoxyphenyl)ethyl)-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-3,4-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-89-8 HCAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[4-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 705978-90-1 HCAPLUS
 CN 2-Piperidinecarboxamide, 1-[4-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-93-4 HCAPLUS
 CN 2-Piperidinecarboxamide, 1-[4-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 705978-94-5 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-[(1-piperidinylcarbonyl)-1-piperidinyl]butyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-95-6 HCAPLUS

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705978-91-2 HCAPLUS
 CN 4-Piperidinecarboxamide, 1-[4-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 705978-92-3 HCAPLUS
 CN 2-Piperidinecarboxamide, 1-[4-[[[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 4-Piperidinecarboxamide, 1-[4-[[[2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)



RN 705978-96-7 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[4-[(1-piperidinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705978-97-8 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 705978-98-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[imino[[2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10727997


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705978-99-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 705979-00-6 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(3,4-dihydro-2(1H)-isoquinolinyl)butyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705979-01-7 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(octahydro-2(1H)-isoquinolinyl)butyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705979-05-1 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(ethyl(4-pyridinylmethyl)amino)butyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705979-06-2 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(3-(dimethylamino)-1-pyrrolidinyl)butyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 705979-02-8 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(methyl(phenylmethyl)amino)butyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 705979-03-9 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(methyl(15)-1-phenylethyl)amino]butyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute Stereochemistry.




RN 705979-04-0 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(methyl(2-(2-pyridinyl)ethyl)amino)butyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705979-07-3 HCAPLUS
CN Proline, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)



RN 705979-08-4 HCAPLUS
CN 3-Piperidinecarboxamide, 1-[4-[[[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorobenzoyl]amino]iminomethyl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 705979-09-5 HCAPLUS
CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[4-(3-hydroxy-1-pyrrolidinyl)butyl]amino]iminomethyl]- (9CI) (CA INDEX NAME)




RN 705979-10-8 HCAPLUS
CN Benzamide, N-[[[4-(3-(acetylmethylamino)-1-pyrrolidinyl)butyl]amino]iminomethyl]-3-fluoro-2-[2-(5-bromo-2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzamide, 2-[2-(3,4-dichlorophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705979-15-3 HCAPLUS
CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705979-16-4 HCAPLUS
CN Benzamide, 2-[2-(3-cyanophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705979-17-5 HCAPLUS
CN Benzamide, 2-[2-(4-bromophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro- (9CI) (CA INDEX NAME)

PAGE 2-A


RN 705979-11-9 HCAPLUS
CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705979-12-0 HCAPLUS
CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 705979-13-1 HCAPLUS
CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-2-[2-(3,5-dimethoxyphenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 705979-14-2 HCAPLUS




RN 705979-18-6 HCAPLUS
CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-2-[2-(4-(1,1-dimethylethyl)phenyl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 705979-19-7 HCAPLUS
CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(4-(trifluoromethoxy)phenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 705979-20-0 HCAPLUS
CN Benzamide, N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 705979-31-3 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CH 1

CRN 705977-44-2
 CHF C26 H34 Br F N4 O2



CH 2


CRN 64-18-6
 CHF C H2 O2

O=CH-OH

RN 705979-32-4 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[(butylamino)iminomethyl]-3-fluorobenzamide (1:1) (9CI) (CA INDEX NAME)


CH 1

CRN 705977-45-3
 CHF C21 H25 Br F N3 O2



CH 2

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CH 2


CRN 64-18-6
 CHF C H2 O2

O=CH-OH

RN 705979-35-7 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[2-(1-pyrrolidinyl)ethyl]amino]methyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 705977-48-6
 CHF C23 H28 Br F N4 O2



CH 2


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 64-18-6
 CHF C H2 O2

O=CH-OH

RN 705979-33-5 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[2-methylpropyl]amino]methyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 705977-46-4
 CHF C21 H25 Br F N3 O2



CH 2

CRN 64-18-6
 CHF C H2 O2

O=CH-OH

RN 705979-34-6 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[(cyclopentylamino)iminomethyl]-3-fluorobenzamide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 705977-47-5
 CHF C22 H25 Br F N3 O2


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 64-18-6
 CHF C H2 O2

O=CH-OH

RN 705979-36-8 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[2-(cyclohexylethyl)amino]iminomethyl]-3-fluorobenzamide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 705977-49-7
 CHF C25 H31 Br F N3 O2




CH 2

CRN 64-18-6
 CHF C H2 O2

O=CH-OH


RN 705979-37-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[1-phenylethyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

10727997


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 705979-38-0 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [imino[(2-thienylmethyl)amino]methyl]benzamide (2:1) (9CI) (CA INDEX
 NAME)
 CM 1
 CRN 705977-51-1
 CMF C22 H21 Br F N3 O2 5




CM 2
 CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-39-1 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [imino[(3-pyridinylmethyl)amino]methyl]benzamide (2:1) (9CI) (CA INDEX
 NAME)
 CM 1
 CRN 705977-52-2
 CMF C23 H22 Br F N4 O2



L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 705979-40-4 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [imino[(1-phenyl-2-(1-pyrrolidinyl)ethyl)amino]methyl]benzamide (2:1)
 (9CI) (CA INDEX NAME)
 CM 1
 CRN 705977-54-4
 CMF C30 H33 Br Cl F N4 O2



CM 2
 CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 705979-42-6 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [imino[[3-(4-morpholinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 705977-55-5
 CMF C24 H30 Br F N4 O3

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CM 2
 CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-40-4 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [imino[[1-phenyl-2-(1-pyrrolidinyl)ethyl]amino]methyl]benzamide (2:1)
 (9CI) (CA INDEX NAME)
 CM 1
 CRN 705977-53-3
 CMF C29 H32 Br F N4 O2




CM 2
 CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-41-5 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2
 CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-43-7 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [[3-(1H-imidazol-1-yl)propyl]amino]methyl]benzamide (1:1) (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 705977-56-6
 CMF C23 H25 Br F N5 O2



CM 2
 CRN 64-18-6

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CMF C H2 O2

O=CH-OH


RN 705979-44-8 HCAPLUS

CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluorobenzamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-57-7

CMF C26 H36 Br F N4 O2



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 705979-45-9 HCAPLUS

CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[3-(4-methyl-1-piperazinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-58-8

CMF C25 H33 Br F N5 O2

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705979-47-1 HCAPLUS

CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[butylamino]iminomethyl]-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-60-2

CMF C19 H24 Br N3 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 705979-48-2 HCAPLUS

CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[imino[[2-methylpropyl]amino]methyl]-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 705977-61-3

CMF C19 H24 Br N3 O2 S



CM 2

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 705979-46-0 HCAPLUS

CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[imino[[3-(1-piperidiny)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-59-9

CMF C25 H32 Br F N4 O2



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 705979-49-3 HCAPLUS

CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[imino[[3-(cyclopentylamino)iminomethyl]-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-62-4

CMF C20 H24 Br N3 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 705979-50-6 HCAPLUS

CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[imino[[3-(pyridinylmethyl)amino]methyl]-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 705977-63-5

CMF C21 H21 Br N4 O2 S

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-51-7 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[2-(1-pyrrolidinyl)ethyl]amino]methyl-3-thiophenecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 705977-64-6
CMF C21 H27 Br N4 O2 S

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

O=CH-OH

RN 705979-53-9 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl-3-thiophenecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-66-8
CMF C20 H25 Br N4 O2 S

CM 2

CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-54-0 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[2-(diethylamino)ethyl]amino]iminomethyl-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-67-9
CMF C21 H29 Br N4 O2 S

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-52-8 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[2-(diethylamino)ethyl]methylamino]iminomethyl-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 705977-65-7
CMF C22 H31 Br N4 O2 S

CM 2

CRN 64-18-6
CMF C H2 O2

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-55-1 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[2-(4-morpholinyl)propyl]amino]methyl-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-68-0
CMF C22 H29 Br N4 O3 S

CM 2

10727997


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-56-2 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[1-ethyl-2-pyrrolidinyl)methyl]amino]iminomethyl]-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-69-1
CMF C22 H29 Br N4 O2 S

CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-57-3 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-thiophenecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 705977-70-4
CMF C24 H35 Br N4 O2 S

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

O=CH-OH

RN 705979-59-5 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino[[3-(1-pyrrolidinyl)propyl]amino]methyl]-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-72-6
CMF C22 H29 Br N4 O2 S

CM 2

CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-60-8 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino[[3-(1-piperidinyl)propyl]amino]methyl]-3-thiophenecarboxamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-73-7
CMF C23 H31 Br N4 O2 S

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-58-4 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[3-(diethylamino)propyl]amino]iminomethyl]-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 705977-71-5
CMF C26 H39 Br N4 O2 S

CM 2

CRN 64-18-6
CMF C H2 O2

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-61-9 HCAPLUS
CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[imino[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]methyl]-3-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-74-8
CMF C22 H27 Br N4 O3 S

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-66-4 HCAPLUS
 CN Formic acid, compd. with 3-fluoro-N-[imino[[3-(1-pyrrolidinyl)propyl]amino]methyl]-2-[2-(1-naphthalenyl)ethyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-79-3
CMF C27 H31 F N4 O

CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-67-5 HCAPLUS
 CN Formic acid, compd. with 3-fluoro-N-[imino[[3-(4-morpholinyl)propyl]amino]methyl]-2-[2-(1-naphthalenyl)ethyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 705977-80-6
CMF C27 H31 F N4 O2

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

O=CH-OH

RN 705979-69-7 HCAPLUS
 CN Formic acid, compd. with 2-[2-(2-bromo-5-chlorophenyl)ethyl]-3-fluoro-N-[imino[[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-82-8
CMF C25 H31 Br Cl F N4 O


CM 2

CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 705979-70-0 HCAPLUS
 CN Formic acid, compd. with 2-[2-(2-bromo-5-chlorophenyl)ethyl]-N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluorobenzamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-83-9
CMF C25 H33 Br Cl F N4 O

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-68-6 HCAPLUS
 CN Formic acid, compd. with N-[[[4-(diethylamino)-1-methylbutyl]amino]iminomethyl]-3-fluoro-2-[2-(1-naphthalenyl)ethyl]benzamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-81-7
CMF C29 H37 F N4 O

CM 2

CRN 64-18-6
CMF C H2 O2


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2


CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 705979-72-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(1H-imidazol-1-yl)propyl]amino]methylene]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 705979-73-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methylene]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 705979-74-4 HCAPLUS

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [(methylamino)[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]methylene)-,
 dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 705979-75-5 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [[(1-methylethyl)amino][3-(2-methyl-1-piperidinyl)propyl]amino]methylene]
 benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-89-5
 CMF C29 H40 Br F N4 O2




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-76-6 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2


CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-78-8 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [[(2-(1-methyl-2-pyrrolidinyl)ethyl)amino](phenylamino)methylene]benzamide
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-92-0
 CMF C30 H34 Br F N4 O2




CM 2

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (diethylamino)-1-methylbutyl]amino)[(1-methylethyl)amino]methylene]-3-
 fluorobenzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 705977-90-8
 CMF C29 H42 Br F N4 O2



CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 705979-77-7 HCAPLUS
 CN Formic acid, compd. with 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-
 [[3-(1H-imidazol-1-yl)propyl]amino][(1-methylethyl)amino]methylene]benzamide
 (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 705977-91-9
 CMF C26 H31 Br F N5 O2

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 705979-79-9 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-N-[[[4-(diethylamino)-1-
 methylbutyl]amino](phenylamino)methylene]-3-fluoro-, dihydrochloride (9CI)
 (CA INDEX NAME)



●2 HCl

RN 705979-80-2 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(2-methyl-
 1-piperidinyl)propyl]amino](phenylamino)methylene]-, dihydrochloride (9CI)
 (CA INDEX NAME)




●2 HCl


RN 705979-81-3 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluoro-N-[[[3-(1H-
 imidazol-1-yl)propyl]amino](phenylamino)methylene]-, dihydrochloride (9CI)
 (CA INDEX NAME)

10727997

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 705979-82-4 HCAPLUS
 CN Benzamide, 2-[2-(5-bromo-7-benzofuranyl)ethyl]-3-fluoro-N-[[3-(4-morpholinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CH:CH=CON:C(NH2)2 and one of R6, R7, R8, R9 or R10 = CON:C(NH2)2,
 CH:CH=CON:C(NH2)2; the other R1 - R10 = H, A, CH, F, Cl, Br, I, SA, OA,
 SO2A, OH, NH2, NHA, NA2, COA, (un)substituted Ph, CH2Ph, OPh, N-, S-,
 O-contg. heterocycle; X = S, SO2, (CH2)n, CO, O, OCH2; A = Cl-8-alkyl; n =
 1 - 3] and their physiol. harmless salts and/or solvates, with
 cardioprotective characteristics and works as inhibitors of the cellular
 Na+/H+ antiporters of the Subtyp 1 are described. Thus,
 N-[3-[2-(3-guanidinocarbonylphenyl)ethyl]benzoyl]guanidine dihydrochloride
 (II·HCl), was prepd. from 3-[2-(3-carboxyphenyl)ethyl]benzoic acid
 and Boc-guanidine in 1-methyl-2-pyrrolidone contg. 2-chloro-1-
 methylpyridinium iodide and Et3N·Me2, followed by hydrolysis with aq.
 HCl. Formulations for use in injections, suppositories, solns., tablets,
 capsules and ampules are given.

IT 374681-40-OP
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent); USES (Uses)

(preparation of cardioprotective bisacylguanidines that work as
 inhibitors of the cellular Na+/H+ antiporters)

RN 374681-40-0 HCAPLUS
 CN Carbamic acid, [1,2-ethanediyl]bis(3,1-phenylenecarbonyliminocarbonimidoyl)
 [bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT 374681-41-1P 374681-43-3P 374681-44-4P
 374681-45-5P 374681-47-7P 374681-76-2P
 374681-77-3P 374681-78-4P 374681-79-5P
 374681-80-8P 374681-81-9P 374681-84-2P
 374682-08-3P, N-[3-[2-(3-Guanidinocarbonylphenyl)ethyl]benzoyl]gua
 nidine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cardioprotective bisacylguanidines that work as
 inhibitors of the cellular Na+/H+ antiporters)



RN 374681-41-1 HCAPLUS
 CN Benzamide, 3,3'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride
 (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 23 Nov 2001
 ACCESSION NUMBER: 2001:850646 HCAPLUS
 DOCUMENT NUMBER: 135:371527
 TITLE: Preparation of bisacylguanidine with cardioprotective
 activity
 INVENTOR(S): Gericke, Rolf; Beier, Norbert
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10024319	A1	20011122	DE 2000-10024319	20000517
WO 2001087829	A1	20011122	WO 2001-EP4425	20010419


V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2000-10024319 A 20000517
 OTHER SOURCE(S): CASREACT 135:371527; MARPAT 135:371527
 GI




AB Bisacylguanidines I [one of R1, R2, R3, R4 or R5 = CON:C(NH2)2,

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 2 HCl

RN 374681-43-3 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-[2-[4-[[[aminoiminomethyl]amino]carbonyl
]phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 374681-44-4 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-2-[2-[3-[[[aminoiminomethyl]amino]carbonyl
]phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374681-45-5 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-2-[2-[4-[[[aminoiminomethyl]amino]carbonyl
]phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10727997

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




●2 HCl

RN 374681-47-7 HCAPLUS
 CN Benzamide, 2,2'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 374681-76-2 HCAPLUS
 CN Benzamide, 4,4'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl


RN 374681-81-9 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-2-[[3-[[[aminoiminomethyl]amino]carbonyl]phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 374681-84-2 HCAPLUS
 CN Benzamide, 2,2'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 374681-77-3 HCAPLUS
 CN Benzamide, 3,3'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 374681-78-4 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-[[4-[[[aminoiminomethyl]amino]carbonyl]phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 374681-79-5 HCAPLUS
 CN Benzamide, 4,4'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 374681-80-8 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-2-[[4-[[[aminoiminomethyl]amino]carbonyl]phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl

RN 374682-08-3 HCAPLUS
 CN Benzamide, 3,3'-(1,2-ethanediyl)bis[N-(aminoiminomethyl)- (9CI) (CA INDEX NAME)



10727997

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 08 Nov 1997

ACCESSION NUMBER: 1997:705845 HCAPLUS

DOCUMENT NUMBER: 127:358717

TITLE: Preparation of substituted benzoylguanidines as diagnostic agent for inhibiting the Na⁺/H⁺ exchanger and diagnosing hypertension and proliferative disorders

INVENTOR(S): Schwark, Jan-Robert; Kleemann, Heinz-Werner; Lang, Hans-Jochen; Weichert, Andreas; Scholz, Wolfgang; Albus, Udo

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 252,786, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5679712	A	19971021	US 1995-459966	19950602
IL 109887	A	19980222	IL 1994-109887	19940603
DE 4441880	A1	19960530	DE 1994-4441880	19941124
US 5849775	A	19981215	US 1997-886037	19970630
PRIORITY APPL. INFO.:			US 1994-252786	B2 19940602
			DE 1994-4441880	19941124
			DE 1993-4318756	A 19930605
			US 1995-459966	A 19950602

OTHER SOURCE(S): MARPAT 127:358717

GI



AB The title compds. [I: R1 = R6C(O) (wherein R6 = C1-8 alkyl, C1-8 perfluoroalkyl, C3-8 alkenyl, etc.); R2 = H, halo, OH, etc.; R3 = R1 or R2; R4, R5 = R2] and their salts, useful for treating arrhythmias, treating or preventing diseases caused by ischemic conditions, for diagnosing hypertension and proliferative disorders, and treating myocardial infarction, angina pectoris, ischemic conditions of the heart, of the peripheral and central nervous systems, or the peripheral organs and limbs, of stroke and of conditions of shock, were prepared. Thus, Fries displacement of 4-acetoxybenzoic acid with AlCl₃ followed by reaction of the resulting 3-acetyl-4-hydroxybenzoic acid with carbonyldiimidazole and guanidine afforded I [R1 = MeCO; R2 = OH; R3-R5 = H] which showed IC₅₀ of 2.0x10⁻⁶ M/L against Na⁺/H⁺ exchange.

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 25 Jun 1996

ACCESSION NUMBER: 1996:365475 HCAPLUS

DOCUMENT NUMBER: 125:33332

TITLE: Benzoylguanidine derivatives as medicaments inhibiting cellular Na⁺/H⁺ exchange.

INVENTOR(S): Kuno, Atsushi; Mizuno, Hiroaki; Yamasaki, Kumi; Inoue, Yoshikazu

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604241	A2	19960215	WO 1995-JP1479	19950725
WO 9604241	A3	19960620		
W: AU, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9506119	A	19960306	ZA 1995-6119	19950721
CA 2196763	A1	19960215	CA 1995-2196763	19950725
AU 9529916	A	19960304	AU 1995-29916	19950725
AU 697748	B2	19981015		
EP 773927	A2	19970521	EP 1995-926026	19950725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1158606	A	19970903	CN 1995-195299	19950725
CN 1070173	B	20010829		
JP 10503770	T	19980407	JP 1996-506385	19950725
JP 3473023	B2	20031202		
IN 1995MA0944	A	20050225	IN 1995-MA944	19950725
TW 426658	B	20010321	TW 1995-84108031	19950802
BR 9502471	A	19960521	BR 1995-2471	19950804
US 5968985	A	19991019	US 1997-776385	19970203
PRIORITY APPL. INFO.:			GB 1994-15852	A 19940805
			GB 1994-22830	A 19941011
			GB 1995-5231	A 19950315
			WO 1995-JP1479	W 19950725

OTHER SOURCE(S): MARPAT 125:33332

GI



II

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 198477-63-3P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzoylguanidines as diagnostic agent for inhibiting the Na⁺/H⁺ exchanger and diagnosing hypertension and proliferative disorders)

RN 198477-63-3 HCAPLUS

CN Benzamide, N-(aminoininomethyl)-3-benzoyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Guanidine derivs. I [R1 = H, hydroxyalkyl, protected hydroxyalkyl, acylalkoxy, acylalkenyl, acyl; R2 = aralkenyl; disubstituted aryl, (un)substituted indenyl, indenyl, dihydrobenzocycloheptenyl, di- to decahydronaphthyl, cyclopentenyl, dihydrothienyl, dihydrofuryl or heterobicyclicyl, alkylthienyl, mono- or dihalothienyl, haloalkylthienyl, acylthienyl, halofuryl, haloalkylfuryl] and their pharmaceutically acceptable salts are claimed. The compds. are strong inhibitors of Na⁺/H⁺ exchange in cells, and are thus useful for the treatment and/or prevention of cardiovascular, cerebrovascular, and renal disease, arteriosclerosis, shock, etc. For example, condensation of guanidine-HCl with Me 3-(benzofuran-4-yl)benzoate in DMF in the presence of NaOMe, and workup and salification of the product, gave title compound II as its methanesulfonate salt. In a test for inhibition of Na propionate-induced swelling of thymocytes in vitro (measure of Na⁺/H⁺ exchanger activation), an exemplary compound had Ki of < 1.0 + 10⁻⁷.

IT 177732-02-4P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoylguanidine derivs. as inhibitors of cellular Na⁺/H⁺ exchange)


RN 177732-02-4 HCAPLUS

CN Benzamide, N-(aminoininomethyl)-3-(1-phenylethenyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 177732-01-3

CMF C16 H15 N3 O



CM 2

CRN 75-75-2


CMF C H4 O3 S



10727997

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 22 Dec 1995
 ACCESSION NUMBER: 1995:994741 HCAPLUS
 DOCUMENT NUMBER: 124:86809
 TITLE: Preparation of (pyrrolyl- and thienylcarbonyl)guanidines as sodium-hydrogen exchange inhibitors, antiarrhythmic agents, and cell proliferation inhibitors
 INVENTOR(S): Kleemann, Heinz-Werner; Lang, Hans-Jochen; Schwack, Jan-Robert; Weichert, Andreas; Scholz, Wolfgang; Albus, Udo
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 48 pp. CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 676395	A2	19951011	EP 1995-105088	19950405
EP 676395	A3	19960306		
EP 676395	B1	20030903		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4412334	A1	19951019	DE 1994-4412334	19940411
AT 248817	T	20030915	AT 1995-105088	19950405
ES 2206471	T3	20040516	ES 1995-105088	19950405
FI 9501681	A	19951012	FI 1995-1681	19950407
AU 9516354	A	19951019	AU 1995-16354	19950407
AU 683722	B2	19971120		
US 5698581	A	19971216	US 1995-418434	19950407
CA 2146707	A1	19951012	CA 1995-2146707	19950410
NO 9501405	A	19951012	NO 1995-1405	19950410
JP 07291927	A	19951107	JP 1995-107811	19950410
ZA 9502930	A	19960126	ZA 1995-2930	19950410
HU 71616	A2	19960129	HU 1995-1035	19950410
CN 1117044	A	19960221	CN 1995-104391	19950410
CN 1073988	B	20011031		
IL 113310	A	20000629	IL 1995-113310	19950410
PRIORITY APPLN. INFO.: DE 1994-4412334			A	19940411
OTHER SOURCE(S):				
GI				




AB Title compds. [1: 1 of R1,R2 = CON:C(NH2)2 and the other = H, halo, alkyl, CON:C(NH2)2, NH2, etc.; R3,R4 = H, halo, cyano, alkyl, Ph, heteroaryl,

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 etc.; Z = SOO-2, O, NR5; R5 = H, alkyl, etc.] were prepd. Thus, Me 1-methylpyrrolyl-2-carboxylate was alkylated with (CF3)2CFI and the product amidated with guanidine to give 1 [R1 = CON:C(NH2)2, R2 = R3 = H, R4 = (CF3)2CF, Z = NMe] which ad IC50 of 0.3µM against Na+/H+ exchange in rabbit erythrocytes in vitro.
 IT 172457-81-7P 172457-85-1P 172461-16-4P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (pyrrolyl- and thienylcarbonyl)guanidines as sodium-hydrogen exchange inhibitors, antiarrhythmic agents, and cell proliferation inhibitors)
 RN 172457-81-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(aminoiminomethyl)-4-(methylsulfonyl)-3-(2-phenylethynyl)-(9CI) (CA INDEX NAME)



RN 172457-85-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(aminoiminomethyl)-4-(methylsulfonyl)-3-(phenylethynyl)-(9CI) (CA INDEX NAME)




RN 172461-16-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(aminoiminomethyl)-3-(phenylethynyl)-4-(trifluoromethyl)-(9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 06 Oct 1995
 ACCESSION NUMBER: 1995:835463 HCAPLUS
 DOCUMENT NUMBER: 123:256771
 TITLE: Guanidine derivatives as inhibitors of Na+/H+ exchange in cells
 INVENTOR(S): Kuno, Atsushi; Inoue, Yoshikazu; Takasugi, Hisashi; Mizuno, Hiroaki; Yamasaki, Kumi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 212 pp. CODEN: PFXXDZ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9426709	A1	19941124	WO 1994-JP786	19940512
W: AU, CA, CN, HU, JP, KR, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
TV 393487	B	20000611	TW 1994-83104223	19940510
CA 2163004	A1	19941124	CA 1994-2163004	19940512
AU 9466912	A	19941212	AU 1994-66912	19940512
AU 685457	B2	19980122		
HU 70206	A2	19950928	HU 1994-3233	19940512
EP 699185	A1	19960306	EP 1994-914623	19940512
EP 699185	B1	20010905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1123545	A	19960529	CN 1994-192121	19940512
CN 1080257	B	20020306		
JP 08511243	T	19961126	JP 1994-525245	19940512
RU 2141946	C1	19991127	RU 1995-122558	19940512
AT 205191	T	20010915	AT 1994-914623	19940512
ES 2159558	T3	20011016	ES 1994-914623	19940512
PT 699185	T	20020130	PT 1994-914623	19940512
ZA 9403388	A	19950123	ZA 1994-3388	19940517
US 5824691	A	19981020	US 1995-532804	19951109
GR 3036549	T3	20011231	GR 2001-401402	20010906
PRIORITY APPLN. INFO.: GB 1993-10074			A	19930517
GB 1993-25268			A	19931210
WO 1994-JP786			W	19940512

OTHER SOURCE(S): MARPAT 123:256771
 GI




II

10727997

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AB The N-benzoylguanidine derivs. or N-(heteroaroyl)guanidine derivs. I (X, Y, Z = nitrogen, methine; R² = H, aryl, etc.; R³ = H, alkoxy, hydromy, etc.) and pharmaceutically acceptable salts thereof were disclosed as pharmaceuticals. I inhibit the sodium/hydrogen exchange in cells and are hence useful for the treatment of cardiovascular diseases, cerebrovascular diseases, renal diseases, arteriosclerosis or shock. A claimed example compound is N-(3-(1H-pyrrol-1-yl)benzoyl)guanidine (i.e., N-(aminoininomethyl)-3-(1H-pyrrol-1-yl)benzamide) (II).
 IT 168621-27-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(aroyl)guanidine derivs. as sodium exchange inhibitors)
 RN 168621-27-0 HCAPLUS
 CN Benzamide, N-(aminoininomethyl)-3-benzoyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 168621-26-9
 CMF C15 H13 N3 O2



CM 2


CRN 75-75-2
 CMF C H4 O3 S



L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 21 Mar 1995
 ACCESSION NUMBER: 1995:426566 HCAPLUS
 DOCUMENT NUMBER: 122:187136
 TITLE: Preparation of substituted benzoylguanidines as inhibitors of cellular Na⁺/H⁺ exchange
 INVENTOR(S): Lang, Hans-Jochen; Weichert, Andreas; Kleemann, Heinz-Werner; Schwark, Jan-Robert; Scholz, Wolfgang; Albus, Udo
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 19 pp.
 CODEN: EPXIXD
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 18
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 612723	A1	19940831	EP 1994-102322	19940216
EP 612723	B1	19970827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 157351	T	19970915	AT 1994-102322	19940216
ES 2107698	T3	19971201	ES 1994-102322	19940216
FI 9400756	A	19940821	FI 1994-756	19940217
FI 114467	B1	20041029		
IL 108697	A	20000716	IL 1994-108697	19940217
CA 2115967	A1	19940821	CA 1994-2115967	19940218
NO 9400563	A	19940822	NO 1994-563	19940218
AU 9455229	A	19940825	AU 1994-55229	19940218
AU 668265	B2	19960426		
ZA 9401119	A	19940830	ZA 1994-1119	19940218
JP 06256291	A	19940913	JP 1994-20762	19940218
JP 3554352	B2	20040818		
HU 70355	A2	19951030	HU 1994-466	19940218
HU 218915	B	20001228		
TW 420659	B	20010201	TW 1994-83102858	19940401
US 5866610	A	19990202	US 1996-683141	19960718
JP 2004189755	A	20040708	JP 2004-87016	20040324
JP 3806431	B2	20060809		
PRIORITY APPLN. INFO.:				
DE 1993-4305250	A	19930220		
JP 1994-20762	A3	19940218		
US 1994-198812	B1	19940218		
US 1995-391272	B1	19950221		

OTHER SOURCE(S): MARPAT 122:187136
 GI



L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title compds. (I; R¹, R², R³ = H, F, Cl, Br, iodo, alkyl; 1 of R¹-R³ = N³, cyano, Oh, alkoxy, etc.), were prepared as inhibitors of the cellular sodium-proton antiporter (no data). Thus, 3,5-dichlorobenzoic acid was stirred with carbonyldiimidazole and then guanidine in THF followed by salification to give 3,5-dichlorobenzoylguanidine hydrochloride.
 IT 161621-81-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted benzoylguanidines as inhibitors of cellular Na⁺/H⁺ exchange)
 RN 161621-81-4 HCAPLUS
 CN Benzamide, N-(aminoininomethyl)-4-(phenylethynyl)-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 26 Nov 1994
 ACCESSION NUMBER: 1994:655423 HCAPLUS
 DOCUMENT NUMBER: 121:255423
 TITLE: Preparation of N-benzoylguanidines as cardiovascular agents
 INVENTOR(S): Weichert, Andreas; Lang, Hans-Jochen; Kleemann, Heinz-Werner; Scholz, Wolfgang; Albus, Udo
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 22 pp.
 CODEN: EPXIXD
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 602522	A1	19940622	EP 1993-119781	19931208
EP 602522	B1	19960529		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 138646	T	19960615	AT 1993-119781	19931208
ES 2087637	T3	19960716	ES 1993-119781	19931208
FI 9305577	A	19940616	FI 1993-5577	19931213
FI 115049	B1	20050228		
AU 9352490	A	19940630	AU 1993-52490	19931213
AU 663425	B2	19951005		
CA 2111385	A1	19940616	CA 1993-2111385	19931214
NO 9304605	A	19940616	NO 1993-4605	19931214
JP 06234727	A	19940823	JP 1993-313040	19931214
JP 3545793	B2	20040721		
HU 70427	A2	19951030	HU 1993-3595	19931215
HU 220224	B	20011128		
US 5670544	A	19970923		
PRIORITY APPLN. INFO.:				
DE 1992-4242192	A	19921215		
US 1993-165667	B1	19931213		
US 1994-337237	B1	19941104		


OTHER SOURCE(S): MARPAT 121:255423
 GI



AB Title compds. (I; R¹ = H, halo, CF₃, cyano, alkylsulfonfyl, etc.; R² = OR¹⁰, NHR¹⁰, CHR¹⁰R¹², CR¹²R¹³OR¹³, COCH₂R¹⁴, etc.; R³ = H, Me, cyano, CF₃, F, Cl, etc.; R¹⁰ = CH₂[CH(OH)]qCH₂OH, (CH₂)pO(CH₂CH₂O)nMe, etc.; R¹², R¹³, R¹⁴ = H, alkyl; n, p = 0-2; q = 0-5) were prepared as cardiovascular agents (no data). Thus, 4,3-R²(MeO₂)C₆H₃CO₂Me (II; R² = Et) was oxidized to I (R² = MeCO) which was condensed with Me₂Zn to give II (R² = HOCH₂Me). The latter was refluxed with H₂N-C(NH₂)₂ to give, after acidification,


10727997

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ED 1.HCl (R1 = H, R2 = HOCH₂, R3 = SO₂Me).
 IT 158607-77-3P 158607-78-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as cardiovascular agent)
 RN 158607-77-3 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 158607-78-4 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-4-(cyclohexylacetyl)-3-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ED 2-3 + 10-6
 IT 154117-55-2P 154117-57-4P 156267-44-6P
 156267-45-7P 156267-46-8P 156267-47-9P
 156267-48-0P 156267-50-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of, as drug)
 RN 154117-55-2 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 154117-57-4 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 156267-44-6 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylethynyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 20 Aug 1994
 ACCESSION NUMBER: 1994:482737 HCAPLUS
 DOCUMENT NUMBER: 121:82737
 TITLE: 3,4,5-substituted benzoylguanidines, process for their preparation, and their use as medicaments
 INVENTOR(S): Weichert, Andreas; Lang, Hans-jochen; Scholz, Wolfgang; Albus, Udo; Lang, Florian
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Can. Pat. Appl., 34 pp.
 CODEN: CPXXEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2099445	A1	19940102	CA 1993-2099445	19930630
IL 106157	A	19991130	IL 1993-106157	19930628
FI 113367	B1	20040415	FI 1993-2998	19930629
AU 9341635	A	19940106	AU 1993-41635	19930630
AU 658309	B2	19950406		
ZA 9304719	A	19940125	ZA 1993-4719	19930630
JP 0616230	A	19940426	JP 1993-159886	19930630
JP 3490739	B2	20040126		
US 5693672	A	19971202	US 1995-451309	19950526
PRIORITY APPLN. INFO.:			DE 1992-4221594	A 19920701
			DE 1992-4224107	A 19920722
			DE 1992-424319	A 19921228
			US 1993-83576	B1 19930630
			US 1994-303006	B1 19940908

OTHER SOURCE(S): MARPAT 121:82737
 GI




AB Title compds. I (R1 = R450m, R5R6NSO2 wherein R4, R5 = C1-8 alkyl, C3-6 alkenyl, etc., m = 0-2, R5 = also H, R6 = H, C1-4 alkyl, etc.; R2 = H, C5-8 alkyl, (substituted) Ph, R12C:C wherein R12 = (substituted) Ph, R15R14N wherein R14, R15 = H, C1-4 alkyl, C1-9 (substituted) heteroaryl, C3-8 cycloalkyl, etc.; R3 = groups as defined for R2), or a salt thereof, are prepared I are suitable as antiarrhythmics (data given) treatment or prophylaxis of cardiac infarct, angina pectoris, heart ischemia, etc. (no data). 3-(Methylsulfonyl)-4-phenylbenzoic acid (preparation given) in THF was treated with carbonyldiimidazole followed by guanidine to give I (R1 = MeSO2, R2 = Ph, R3 = H) (II). The antiarrhythmic effect was demonstrated with II by inhibition of Na⁺/H⁺ exchanger of rabbit erythrocytes with IC50

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 156267-45-7 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylethynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 156267-46-8 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-4-(cyclohexylethynyl)-3-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 156267-47-9 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-4-(cyclohexylethynyl)-3-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10727997


L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 156267-49-0 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 156267-50-4 HCAPLUS
 CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 14 May 1994

ACCESSION NUMBER: 1994:244385 HCAPLUS

DOCUMENT NUMBER: 120:244385

TITLE: Preparation of benzoylguanidines as proton-sodium

exchange inhibitors

INVENTOR(S): Weichert, Andreas; Lang, Hans Jochen; Scholz,

Wolfgang; Albus, Udo; Lang, Florian

SOURCE: Hoechst A.-G., Germany

Eur. Pat. Appl., 15 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 577024	A1	19940105	EP 1993-110195	19930625
EP 577024	B1	19961016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 144248	T	19961115	AT 1993-110195	19930625
ES 2092729	T3	19961201	ES 1993-110195	19930625
NO 9302392	A	19940103	NO 1993-2392	19930630
NO 179673	B	19960819		
NO 179673	C	19961127		
ZA 9304719	A	19940125	ZA 1993-4719	19930630
US 5693672	A	19971202	US 1995-451309	19950526

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

MARPAT 120:244385

G1



AB Title compds. (I: R1 = R4SOO-2, R5R6NSO2; R2,R3 = H, alkyl, CH:CHPh, C.tplbond.CPh, etc.; R4,R5 = alk(en)yl, phenylalkyl, etc.) were prepared Thus, 4,3-Br(MeO2S)C6H3CO2Me was condensed with cyclopentylzinc chloride and the product converted to I.HCl (R1 = SO2Me, R2 = cyclopentyl, R3 = H) which had IC50 of 1x10-7M for inhibition of the rabbit erythrocyte Na+/H+-exchanger in vitro.

IT 154117-53-OP 154117-54-1P 154117-55-2P

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


154117-57-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as proton-sodium exchange inhibitor)

RN 154117-53-0 HCAPLUS


CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(2-phenylethenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 154117-54-1 HCAPLUS

CN Benzamide, N-(aminoiminomethyl)-4-(2-cyclohexylethenyl)-3-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 154117-55-2 HCAPLUS

CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 154117-57-4 HCAPLUS

CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10727997

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 12 May 1984
 ACCESSION NUMBER: 1969:79651 HCAPLUS
 DOCUMENT NUMBER: 70:79651
 TITLE: Amine addition products of nitroaminocarboxy alkali metal phenolates for use as propellant combustion catalysts
 INVENTOR(S): Henderson, Lionel A.
 PATENT ASSIGNEE(S): Standard Oil Co.
 SOURCE: U.S., 4 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3420874	A	19691017	US 1962-227048	19620928
PRIORITY APPLN. INFO.: US 1962-227048 A 19620928				
AB Mixed salts of nitrocarboxyhydroxybenzene produced by reaction of nitrated salicylic acid or nitrated alkylene disalicylic acid (where the alkylene is a C1-3 bridge), an amine, and an alkali metal lower alcoholate give combustion catalysts for NH4NO3-based propellants which ensure smooth even burning and produce a min. amount of smoke and ash. Typical catalysts used to an extent of 1-7% are produced from 3,5-dinitro-1-guanidinumcarboxy-2-sodium phenolate prepared from 3,5-dinitrosalicylic acid, guanidine, and NaOMe and ethylenediaminebis(carboxy-3,5-dinitro-2-sodium phenylate) prepared from ethylenediamine and 2 moles each of 3,5-dinitrosalicylic acid and NaOMe. In propellant compns., most conventional additives may also be present. Thus, a propellant composition was prepared from NH4NO3 (30-80 mesh) 64.62, cellulose acetate 9.15, tri-Et citrate 10.15, dinitro-phenoxyethanol 9.30, C 3.60, graphite 0.05, N-phenylmorpholine 1.25, and 5,5'-methylenebis(3,3'-dinitro-1,1'-guanidinumcarboxy-2,2'-sodium phenylate) 1.88%, burning rate 0.062 in./sec., n 0.487, op 0.075, sk 0.148, in which n = pressure exponent, op = temperature coefficient at constant pressure, and sk = temperature coefficient at constant nozzle throat area and constant burning surface area. A similar composition catalyzed with the usual Na barbiturate showed corresponding values of 0.074, 0.63, 0.09, and 0.24, resp., proving the superiority of the new catalysts.				
IT 13081-08-8 RL: CAT (Catalyst use); USES (Uses) (catalysts, for combustion of propellants)				
RN 13081-08-8 HCAPLUS				
CN Salicylamide, 5,5'-methylenebis[N-amidino-3-nitro-, disodium salt (8CI) (CA INDEX NAME)]				

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 2 Na

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 22 Apr 2001
 ACCESSION NUMBER: 1966:403390 HCAPLUS
 DOCUMENT NUMBER: 65:3390
 ORIGINAL REFERENCE NO.: 65:566h,567a-c,568a
 TITLE: Ammonium nitrate propellants
 INVENTOR(S): Henderson, Lionel A.
 PATENT ASSIGNEE(S): Standard Oil Co.
 SOURCE: 4 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3247035		19660419	US 1963-308920	19630627
PRIORITY APPLN. INFO.: US 19630627				
AB Compns. comprising (by weight) about 0.1-15% nitroaminocarboxyalkali metal phenolate (e.g. 2,3,5-NaO(O2N)2C6H2CO2H. (H2N)2C=NH (I), N,N'-piperazinobis(1-carboxy-3,5-dinitro-2-sodium phenolate), ethylenediaminebis(1-carboxy-3,5-dinitro-2-sodium phenolate), or 5,5-methylenebis(3-nitro-1-guanidinumcarboxy-2-sodium phenolate) as combustion catalyst, 10-40% oxidizable organic binder material (cellulose ester of a C2-4 alkanolic acid, and a plasticizer) and 60-80% NH4NO3, have superior ignitability characteristics at even the lowest atmos. temps. and show smooth, uniform burning properties at low burning rates. These compns. with an alkali metal barbiturate added have exceptionally low pressure exponents and simultaneously very good temperature coeffs. Reaction of equal moles guanidine and 3,5-dinitrosalicylic acid in MeOH and addition of the theoretical amount of NaOMe gives I, which ppts. in crystalline form. The other combustion catalysts are similarly prepared. The propellant compns. are prepared by blending the ingredients in a one quart laboratory mixer for 1 hr. at about 212°F., after which the pasty mass is compression-molded into a 0.5-in. thick slab, which is allowed to cool to room temperature. The molded compns. are then saved into strips for use in Crawford bomb burning rate tests, which are carried out at different pressures to determine the pressure exponents(n). In tests to determine temperature coeffs. at both constant pressure (op) and constant nozzle size (sk) a propellant strand is brought to the desired temperature by storage at that temperature. A composition containing (by weight) 61.00% NH4NO3, 9.79% cellulose acetate (about 55% HOAc equivalent), 11.25% tri-Et acetylcitrate, 9.90% dinitrophenoxyethanol (28% diether), 3.00% C, 2.06% I, 2.00% mono-Na barbiturate, 0.50% N-phenylmorpholine, and 0.50% tolylenediamine gives a burning rate of 0.070 in./sec. at 1000 psia. and 70°F., with n = 0.466. The temperature coeffs. op and sk are 0.100 and 0.19, resp. The compns. described give much less ash formation at a given burning rate than do other propellants containing organic compds. of alkali metals.				
IT 98144-10-6, Sodium, [methylenebis[[2-(amidinocarbamoyl)-6-nitro-p-phenylene]oxy]]di-				
(as combustion catalyst in NH4NO3 propellants)				
RN 98144-10-6 HCAPLUS				
CN Sodium, [methylenebis[[2-(amidinocarbamoyl)-6-nitro-p-phenylene]oxy]]di-				
(7CI) (CA INDEX NAME)]				

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 Na

IT 802562-85-2, Salicylamide, 5,5'-methylenebis[N-amidino-3-nitro-
 (disodium derivative, as combustion catalyst in NH4NO3 propellants)
 RN 802562-85-2 HCAPLUS
 CN Salicylamide, 5,5'-methylenebis[N-amidino-3-nitro- (8CI) (CA INDEX NAME)]



10727997

=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

76.38

TOTAL

SESSION

248.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

ENTRY

-10.92

TOTAL

SESSION

-10.92

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:15:53 ON 06 MAR 2007